IBDEI0MR ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,10226,2)
;;=^5002642
;;^UTILITY(U,$J,358.3,10227,0)
;;=I10.^^39^432^1
;;^UTILITY(U,$J,358.3,10227,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10227,1,3,0)
;;=3^Essential/Primary Hypertension
;;^UTILITY(U,$J,358.3,10227,1,4,0)
;;=4^I10.
;;^UTILITY(U,$J,358.3,10227,2)
;;=^5007062
;;^UTILITY(U,$J,358.3,10228,0)
;;=I11.0^^39^432^12
;;^UTILITY(U,$J,358.3,10228,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10228,1,3,0)
;;=3^Hypertensive Heart Disease w/ Heart Failure
;;^UTILITY(U,$J,358.3,10228,1,4,0)
;;=4^I11.0
;;^UTILITY(U,$J,358.3,10228,2)
;;=^5007063
;;^UTILITY(U,$J,358.3,10229,0)
;;=I11.9^^39^432^13
;;^UTILITY(U,$J,358.3,10229,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10229,1,3,0)
;;=3^Hypertensive Heart Disease w/o Heart Failure
;;^UTILITY(U,$J,358.3,10229,1,4,0)
;;=4^I11.9
;;^UTILITY(U,$J,358.3,10229,2)
;;=^5007064
;;^UTILITY(U,$J,358.3,10230,0)
;;=I12.0^^39^432^5
;;^UTILITY(U,$J,358.3,10230,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10230,1,3,0)
;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
;;^UTILITY(U,$J,358.3,10230,1,4,0)
;;=4^I12.0
;;^UTILITY(U,$J,358.3,10230,2)
;;=^5007065
;;^UTILITY(U,$J,358.3,10231,0)
;;=I12.9^^39^432^4
;;^UTILITY(U,$J,358.3,10231,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10231,1,3,0)
;;=3^Hypertensive CKD w/ Stage 1-4 CKD
;;^UTILITY(U,$J,358.3,10231,1,4,0)
;;=4^I12.9
;;^UTILITY(U,$J,358.3,10231,2)
;;=^5007066
;;^UTILITY(U,$J,358.3,10232,0)
;;=I13.0^^39^432^8
;;^UTILITY(U,$J,358.3,10232,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10232,1,3,0)
;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
;;^UTILITY(U,$J,358.3,10232,1,4,0)
;;=4^I13.0
;;^UTILITY(U,$J,358.3,10232,2)
;;=^5007067
;;^UTILITY(U,$J,358.3,10233,0)
;;=I13.10^^39^432^10
;;^UTILITY(U,$J,358.3,10233,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10233,1,3,0)
;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
;;^UTILITY(U,$J,358.3,10233,1,4,0)
;;=4^I13.10
;;^UTILITY(U,$J,358.3,10233,2)
;;=^5007068
;;^UTILITY(U,$J,358.3,10234,0)
;;=I13.11^^39^432^11
;;^UTILITY(U,$J,358.3,10234,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10234,1,3,0)
;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD
;;^UTILITY(U,$J,358.3,10234,1,4,0)
;;=4^I13.11
;;^UTILITY(U,$J,358.3,10234,2)
;;=^5007069
;;^UTILITY(U,$J,358.3,10235,0)
;;=I13.2^^39^432^9
;;^UTILITY(U,$J,358.3,10235,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10235,1,3,0)
;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD
;;^UTILITY(U,$J,358.3,10235,1,4,0)
;;=4^I13.2
;;^UTILITY(U,$J,358.3,10235,2)
;;=^5007070
;;^UTILITY(U,$J,358.3,10236,0)
;;=I15.0^^39^432^15
;;^UTILITY(U,$J,358.3,10236,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10236,1,3,0)
;;=3^Renovascular Hypertension
;;^UTILITY(U,$J,358.3,10236,1,4,0)
;;=4^I15.0
;;^UTILITY(U,$J,358.3,10236,2)
;;=^5007071
;;^UTILITY(U,$J,358.3,10237,0)
;;=I15.1^^39^432^3
;;^UTILITY(U,$J,358.3,10237,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10237,1,3,0)
;;=3^Hypertension Secondary to Oth Renal Disorders
;;^UTILITY(U,$J,358.3,10237,1,4,0)
;;=4^I15.1
;;^UTILITY(U,$J,358.3,10237,2)
;;=^5007072
;;^UTILITY(U,$J,358.3,10238,0)
;;=I15.2^^39^432^2
;;^UTILITY(U,$J,358.3,10238,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,10238,1,3,0)
;;=3^Hypertension Secondary to Endocrine Disorders
;;^UTILITY(U,$J,358.3,10238,1,4,0)
;;=4^I15.2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0MR 3767 printed Apr 09, 2024@21:15:57 Page 2
IBDEI0MR ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,10226,2)
+2 ;;=^5002642
+3 ;;^UTILITY(U,$J,358.3,10227,0)
+4 ;;=I10.^^39^432^1
+5 ;;^UTILITY(U,$J,358.3,10227,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,10227,1,3,0)
+8 ;;=3^Essential/Primary Hypertension
+9 ;;^UTILITY(U,$J,358.3,10227,1,4,0)
+10 ;;=4^I10.
+11 ;;^UTILITY(U,$J,358.3,10227,2)
+12 ;;=^5007062
+13 ;;^UTILITY(U,$J,358.3,10228,0)
+14 ;;=I11.0^^39^432^12
+15 ;;^UTILITY(U,$J,358.3,10228,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,10228,1,3,0)
+18 ;;=3^Hypertensive Heart Disease w/ Heart Failure
+19 ;;^UTILITY(U,$J,358.3,10228,1,4,0)
+20 ;;=4^I11.0
+21 ;;^UTILITY(U,$J,358.3,10228,2)
+22 ;;=^5007063
+23 ;;^UTILITY(U,$J,358.3,10229,0)
+24 ;;=I11.9^^39^432^13
+25 ;;^UTILITY(U,$J,358.3,10229,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,10229,1,3,0)
+28 ;;=3^Hypertensive Heart Disease w/o Heart Failure
+29 ;;^UTILITY(U,$J,358.3,10229,1,4,0)
+30 ;;=4^I11.9
+31 ;;^UTILITY(U,$J,358.3,10229,2)
+32 ;;=^5007064
+33 ;;^UTILITY(U,$J,358.3,10230,0)
+34 ;;=I12.0^^39^432^5
+35 ;;^UTILITY(U,$J,358.3,10230,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,10230,1,3,0)
+38 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
+39 ;;^UTILITY(U,$J,358.3,10230,1,4,0)
+40 ;;=4^I12.0
+41 ;;^UTILITY(U,$J,358.3,10230,2)
+42 ;;=^5007065
+43 ;;^UTILITY(U,$J,358.3,10231,0)
+44 ;;=I12.9^^39^432^4
+45 ;;^UTILITY(U,$J,358.3,10231,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,10231,1,3,0)
+48 ;;=3^Hypertensive CKD w/ Stage 1-4 CKD
+49 ;;^UTILITY(U,$J,358.3,10231,1,4,0)
+50 ;;=4^I12.9
+51 ;;^UTILITY(U,$J,358.3,10231,2)
+52 ;;=^5007066
+53 ;;^UTILITY(U,$J,358.3,10232,0)
+54 ;;=I13.0^^39^432^8
+55 ;;^UTILITY(U,$J,358.3,10232,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,10232,1,3,0)
+58 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
+59 ;;^UTILITY(U,$J,358.3,10232,1,4,0)
+60 ;;=4^I13.0
+61 ;;^UTILITY(U,$J,358.3,10232,2)
+62 ;;=^5007067
+63 ;;^UTILITY(U,$J,358.3,10233,0)
+64 ;;=I13.10^^39^432^10
+65 ;;^UTILITY(U,$J,358.3,10233,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,10233,1,3,0)
+68 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
+69 ;;^UTILITY(U,$J,358.3,10233,1,4,0)
+70 ;;=4^I13.10
+71 ;;^UTILITY(U,$J,358.3,10233,2)
+72 ;;=^5007068
+73 ;;^UTILITY(U,$J,358.3,10234,0)
+74 ;;=I13.11^^39^432^11
+75 ;;^UTILITY(U,$J,358.3,10234,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,10234,1,3,0)
+78 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD
+79 ;;^UTILITY(U,$J,358.3,10234,1,4,0)
+80 ;;=4^I13.11
+81 ;;^UTILITY(U,$J,358.3,10234,2)
+82 ;;=^5007069
+83 ;;^UTILITY(U,$J,358.3,10235,0)
+84 ;;=I13.2^^39^432^9
+85 ;;^UTILITY(U,$J,358.3,10235,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,10235,1,3,0)
+88 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD
+89 ;;^UTILITY(U,$J,358.3,10235,1,4,0)
+90 ;;=4^I13.2
+91 ;;^UTILITY(U,$J,358.3,10235,2)
+92 ;;=^5007070
+93 ;;^UTILITY(U,$J,358.3,10236,0)
+94 ;;=I15.0^^39^432^15
+95 ;;^UTILITY(U,$J,358.3,10236,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,10236,1,3,0)
+98 ;;=3^Renovascular Hypertension
+99 ;;^UTILITY(U,$J,358.3,10236,1,4,0)
+100 ;;=4^I15.0
+101 ;;^UTILITY(U,$J,358.3,10236,2)
+102 ;;=^5007071
+103 ;;^UTILITY(U,$J,358.3,10237,0)
+104 ;;=I15.1^^39^432^3
+105 ;;^UTILITY(U,$J,358.3,10237,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,10237,1,3,0)
+108 ;;=3^Hypertension Secondary to Oth Renal Disorders
+109 ;;^UTILITY(U,$J,358.3,10237,1,4,0)
+110 ;;=4^I15.1
+111 ;;^UTILITY(U,$J,358.3,10237,2)
+112 ;;=^5007072
+113 ;;^UTILITY(U,$J,358.3,10238,0)
+114 ;;=I15.2^^39^432^2
+115 ;;^UTILITY(U,$J,358.3,10238,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,10238,1,3,0)
+118 ;;=3^Hypertension Secondary to Endocrine Disorders
+119 ;;^UTILITY(U,$J,358.3,10238,1,4,0)
+120 ;;=4^I15.2
